Assembly committee approves bill restricting biosimilar substitutions

08/23/2013 | California Healthline · Drug Store News

A bill that would require pharmacists to inform prescribers when they substitute a biosimilar drug for a biologic medication was approved by a California Assembly committee. The bill, SB 598, also would prevent the substitution of biosimilars when prescriptions include a "do not substitute" direction.

View Full Article in:

California Healthline · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA